Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 100

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 100
---
 any court to have infringed a third party’s intellectual property rights, Kadimastem cannot guarantee that its technology or use of its technology does not infringe third-party patents. It is also possible that it has failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000, and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing, which is referred to as the priority date. Therefore, patent applications covering its technology could have been filed by others without its knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover Kadimastem’s technology.

Kadimastem may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to its technology, including inter parties review, interference, or derivation proceedings before the U.S. PTO and similar bodies in other countries. Third parties may assert infringement claims against Kadimastem based on existing intellectual property rights and intellectual property rights that may be granted in the future.

If Kadimastem is found to infringe a third party’s intellectual property rights, Kadimastem could be required to obtain a license from such third party to continue developing and marketing its technology. However, Kadimastem may not be able to obtain any required license on commercially reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in the introduction of its products or lead to prohibition of the manufacture or sale of products by it. Even if Kadimastem were able to obtain a license, Kadimastem could be non-exclusive, thereby giving its competitors access to the same technologies licensed to it. Kadimastem could be forced, including by court order, to cease commercializing the infringing technology. In addition, Kadimastem could be found liable for monetary damages, including treble damages and attorneys’ fees if Kadimastem is found to have willfully infringed a patent. A finding of infringement could prevent Kadimastem from commercializing its technology or force Kadimastem to cease some of its business operations, which could materially harm Kadimastem’s business. Claims that Kadimastem has misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on its business.

Kad